江西医药
江西醫藥
강서의약
JIANGXI MEDICAL JOURNAL
2015年
8期
746-747
,共2页
2型糖尿病%沙格列汀%糖化血红蛋白%DPP-4
2型糖尿病%沙格列汀%糖化血紅蛋白%DPP-4
2형당뇨병%사격렬정%당화혈홍단백%DPP-4
Type 2 diabetes mellitus%Saxagliptin%HbA1c%Dipeptidyl Peptidase-4
目的：观察单用诺和锐30血糖控制不佳的2型糖尿病患者加用沙格列汀治疗的疗效与安全性。方法将2014年1月-2014年10月我院就诊的96例应用诺和锐30治疗但血糖控制不佳的2型糖尿病患者随机分成两组，试验组诺和锐30基础上加用沙格列汀5mg每日1次口服；对照组患者增加诺和锐30剂量进行治疗，共治疗12周，观察两组患者各项指标的变化及发生不良反应的情况。结果治疗12周后，两组糖化血红蛋白（HbA1c）、空腹血糖（FBG）、餐后2h血糖（2hBG）均显著降低（均P＜0.05），有统计学意义。对照组在治疗12周后诺和锐30的剂量平均增加24U，试验组诺和锐30的剂量平均减少4U。与对照组比较，试验组的2hBG下降幅度更大（P＜0.05），且低血糖发生率、BMI均较对照组明显下降（均P＜0.05）。结论沙格列汀联合诺和锐30可显著改善2型糖尿病患者的血糖，尤其是餐后血糖，同时可以减少胰岛素用量、减轻体重及发生低血糖的风险。
目的：觀察單用諾和銳30血糖控製不佳的2型糖尿病患者加用沙格列汀治療的療效與安全性。方法將2014年1月-2014年10月我院就診的96例應用諾和銳30治療但血糖控製不佳的2型糖尿病患者隨機分成兩組，試驗組諾和銳30基礎上加用沙格列汀5mg每日1次口服；對照組患者增加諾和銳30劑量進行治療，共治療12週，觀察兩組患者各項指標的變化及髮生不良反應的情況。結果治療12週後，兩組糖化血紅蛋白（HbA1c）、空腹血糖（FBG）、餐後2h血糖（2hBG）均顯著降低（均P＜0.05），有統計學意義。對照組在治療12週後諾和銳30的劑量平均增加24U，試驗組諾和銳30的劑量平均減少4U。與對照組比較，試驗組的2hBG下降幅度更大（P＜0.05），且低血糖髮生率、BMI均較對照組明顯下降（均P＜0.05）。結論沙格列汀聯閤諾和銳30可顯著改善2型糖尿病患者的血糖，尤其是餐後血糖，同時可以減少胰島素用量、減輕體重及髮生低血糖的風險。
목적：관찰단용낙화예30혈당공제불가적2형당뇨병환자가용사격렬정치료적료효여안전성。방법장2014년1월-2014년10월아원취진적96례응용낙화예30치료단혈당공제불가적2형당뇨병환자수궤분성량조，시험조낙화예30기출상가용사격렬정5mg매일1차구복；대조조환자증가낙화예30제량진행치료，공치료12주，관찰량조환자각항지표적변화급발생불량반응적정황。결과치료12주후，량조당화혈홍단백（HbA1c）、공복혈당（FBG）、찬후2h혈당（2hBG）균현저강저（균P＜0.05），유통계학의의。대조조재치료12주후낙화예30적제량평균증가24U，시험조낙화예30적제량평균감소4U。여대조조비교，시험조적2hBG하강폭도경대（P＜0.05），차저혈당발생솔、BMI균교대조조명현하강（균P＜0.05）。결론사격렬정연합낙화예30가현저개선2형당뇨병환자적혈당，우기시찬후혈당，동시가이감소이도소용량、감경체중급발생저혈당적풍험。
Objective To study the safety and efficacy of Saxagliptin combined with insulin aspart 30 injection (BIAsp30) in treatment of patients with type 2 diabetes. Methods 96 patients with T2DM inadequately controlled with BIAsp30 were randomly divided into 2 groups with 12 weeks of treatment. The trial group were given oral Saxagliptin 5mg once a day combined with BI-Asp30 insulin injections twice a day. The control group were only given BIAsp30 insulin injections twice a day. The changes of HbA1c,FBG,2hBG and body mass index (BMI) were observed in two groups. Results After 12 weeks treatments,the HbA1c, FBG,2hBG were significantly lower than that before treatment in two groups (all P<0.05),the insulin dosage of control group in-creased 24U,but that of trial group decreased 4U. Compared with the control group,2hBG level in trial group was significantly decreased (P<0.05),incidence of hypoglycaemia and BMI in trial group were significantly reduced (all P<0.05). Conclusion Saxagliptin combined with BIAsp30 in treatment of patients with T2DM was safe and effective to improve the glycaemia control ,es-pecially the 2hBG level,and the drugs can reduce the dosage of insulin,lose weight and decrease the risk of hypoglycaemia.
